Both Aurora kinases A and B have been linked to tumorigenesis and previous publication highlight the importance of Aurora A inhibition: Kelly et al. showed preclinical activity of Alisertib, a selective Aurora A inhibitor as a single agent or in combination with nilotinib [76] in CML cells bearing wild-type or T315I BCR-ABL. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.